Arvinas to Participate in Upcoming Virtual Investor Conferences
November 25 2020 - 7:00AM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that management will participate in
two upcoming virtual investor conferences:
Piper Sandler 32nd Annual Virtual Healthcare
Conference on Tuesday, December 1, 2020. A
pre-recorded fireside chat held with John Houston, Ph.D., President
and Chief Executive Officer, and Ian Taylor, Ph.D., Chief
Scientific Officer, is available here and on the Events +
Presentations section of the Company’s website.
3rd Annual Evercore ISI
HealthCONx Virtual
Conference on Thursday, December 3, 2020. Ian
Taylor, Ph.D., Chief Scientific Officer, and Randy Teel, Ph.D.,
Vice President of Corporate Development, will participate in a
fireside chat at 8:50 a.m. ET. A live audio webcast of
the presentation will be available here and on the Events +
Presentations section of the Company’s website.
About ArvinasArvinas is a clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients suffering from debilitating and life-threatening diseases
through the discovery, development, and commercialization of
therapies that degrade disease-causing proteins. Arvinas uses its
proprietary PROTAC® Discovery Engine platform to engineer
proteolysis targeting chimeras, or PROTAC® targeted protein
degraders, that are designed to harness the body’s own natural
protein disposal system to selectively and efficiently degrade and
remove disease-causing proteins. In addition to its robust
preclinical pipeline of PROTAC® protein degraders against validated
and “undruggable” targets, the company has two clinical-stage
programs: ARV-110 for the treatment of men with metastatic
castrate-resistant prostate cancer; and ARV-471 for the treatment
of patients with locally advanced or metastatic ER+/HER2- breast
cancer. For more information, visit www.arvinas.com.
Contacts for
ArvinasInvestorsWill
O’Connor, Stern Investor Relations ir@arvinas.com
MediaKirsten Owens, Arvinas
Communicationskirsten.owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Apr 2023 to Apr 2024